*General (body as a whole): [[fever]] (sometimes accompanied by shaking [[chills]] usually occurring within 15 to 20 minutes after initiation of treatment); [[malaise]]; [[weight loss]].
*Local: pain at the injection site with or without [[phlebitis]] or [[thrombophlebitis]].
*Musculoskeletal: [[generalized pain]], including muscle and joint pains.
*Neurologic: [[headache]].
*Renal: decreased [[renal function]] and renal function abnormalities including: [[azotemia]], [[hypokalemia]], [[hyposthenuria]], [[renal tubular acidosis]]; and [[nephrocalcinosis]]. These usually improve with interruption of therapy. However, some permanent impairment often occurs, especially in those patients receiving large amounts (over 5 g) of amphotericin B or receiving other [[nephrotoxic agents]]. In some patients hydration and [[sodium]] repletion prior to amphotericin B administration may reduce the risk of developing [[nephrotoxicity]]. Supplemental [[alkali]] medication may decrease [[renal tubular acidosis]].
The following adverse reactions have also been reported:
*General (body as a whole): [[flushing]].
*Allergic: anaphylactoid and other allergic reactions; [[bronchospasm]]; [[wheezing]].
*Dermatologic: rash, in particular maculopapular; pruritus. Skin exfoliation, toxic epidermal necrolysis, and Stevens-Johnson syndrome have been reported during post-marketing surveillance.
*Neurologic: convulsions; hearing loss; tinnitus; transient vertigo; visual impairment; diplopia; peripheral neuropathy; encephalopathy (see PRECAUTIONS); other neurologic symptoms.
*Renal: acute renal failure; anuria; oliguria. Nephrogenic diabetes insipidus has been reported during post-marketing surveillance.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Body as a Whole=====
*[[Fever]] (sometimes accompanied by shaking [[chills]] usually occurring within 15 to 20 minutes after initiation of treatment)
*[[Malaise]]
*[[Weight loss]]
=====Cardiopulmonary=====
*[[Hypotension]]
*[[Tachypnea]]
=====Gastrointestinal=====
*[[Anorexia]]
*[[Nausea]]
*[[Vomiting]]
*[[Diarrhea]]
*[[Dyspepsia]]
*Cramping [[epigastric pain]]
=====Cardiovascular=====
=====Hematologic=====
*Normochromic, normocytic [[anemia]].
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Local=====
*Pain at the injection site with or without [[phlebitis]] or [[thrombophlebitis]].
=====Musculoskeletal=====
*[[Generalized pain]], including muscle and joint pains.
=====Neurologic=====
=====Neurologic=====
*[[Headache]]
=====Renal=====
*Decreased [[renal function]] and renal function abnormalities including
**[[Azotemia]]
**[[Hypokalemia]]
**[[Hyposthenuria]]
**[[Renal tubular acidosis]]
**[[Nephrocalcinosis]]. These usually improve with interruption of therapy. However, some permanent impairment often occurs, especially in those patients receiving large amounts (over 5 g) of amphotericin B or receiving other [[nephrotoxic agents]].
**In some patients hydration and [[sodium]] repletion prior to amphotericin B administration may reduce the risk of developing [[nephrotoxicity]]. Supplemental [[alkali]] medication may decrease [[renal tubular acidosis]].
The following adverse reactions have also been reported:
=====General (body as a whole)=====
*[[Flushing]].
=====Respiratory=====
=====Allergic=====
*[[Anaphylactoid]] and other allergic reactions
*[[Bronchospasm]]
*[[Wheezing]]
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Cardiopulmonary=====
*[[Cardiac arrest]]
*[[Shock]]
*[[Cardiac failure]]
*[[Pulmonary edema]]
*[[Hypersensitivity pneumonitis]]
*[[Arrhythmias]], including [[ventricular fibrillation]]
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
WARNING
See full prescribing information for complete Boxed Warning.
This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts.
Amphotericin B for Injection should no be given in doses greater than 1.5 mg/kg.
EXERCISE CAUTION to prevent inadvertent overdosage, which may result in potentially fatal cardiac or cardiopulmonary arrest. Verify the product name and dosage pre-administration, especially if dose exceeds 1.5 mg/kg.
Amphotericin B for Injection should be administered by slow intravenous infusion. Intravenous infusion should be given over a period of approximately 2 to 6 hours (depending on the dose) observing the usual precautions for intravenous therapy. The recommended concentration for intravenous infusion is 0.1 mg/mL (1mg/10mL). Since patient tolerance varies greatly, the dosage of amphotericin B must be individualized and adjusted according to the patient's clinical status (e.g., site and severity of infection, etiologic agent, cardio-renal function, etc.). A single intravenous test dose (1 mg in 20 mL of 5% dextrose solution) administered over 20 to 30 minutes may be preferred. The patient's temperature, pulse, respiration, and blood pressure should be recorded every 30 minutes for 2 to 4 hours.
In patients with good cardio-renal function and a well tolerated test dose, therapy is usually initiated with a daily dose of 0.25 mg/kg of body weight. However, in those patients having severe and rapidly progressive fungal infection, therapy may be initiated with a daily dose of 0.3 mg/kg of body weight. In patients with impaired cardio-renal function or a severe reaction to the test dose, therapy should be initiated with smaller daily doses (i.e., 5 to 10 mg). Depending on the patient's cardio-renal status, doses may gradually be increased by 5 to 10 mg per day to final daily dosage of 0.5 to 0.7 mg/kg.
There are insufficient data presently available to define total dosage requirements and duration of treatment necessary for eradication of specific mycoses. The optimal dose is unknown. Total daily dosage may range up to 1.0 mg/kg per day or up to 1.5 mg/kg when given on alternate days.
Sporotrichosis: Therapy with intravenous amphotericin B for sporotrichosis has ranged up to nine months with a total dose up to 2.5 g.
Aspergillosis: Aspergillosis has been treated with amphotericin B intravenously for a period up to 11 months with a total dose up to 3.6 g.
Rhinocerebral phycomycosis: This fulminating disease generally occurs in association with diabetic ketoacidosis. It is, therefore, imperative that diabetic control be restored in order for treatment with Amphotericin B for Injection to be successful. In contradistinction, pulmonary phycomycosis, which is more common in association with hematologic malignancies, is often an incidental finding at autopsy. A cumulative dose of at least 3 g of amphotericin B is recommended to treat rhinocerebral phycomycosis. Although a total dose of 3 to 4 g will infrequently cause lasting renal impairment, this would seem a reasonable minimum where there is clinical evidence of invasion of deep tissue. Since rhinocerebral phycomycosis usually follows a rapidly fatal course, the therapeutic approach must necessarily be more aggressive than that used in more indolent mycoses.
Amphotericin B deoxycholate: 0.5–1.0 mg/kg daily IV
Amphotericin B Lipid Formulation: 3–5 mg/kg daily IV
Non–Guideline-Supported Use
Neonatal Candidiasis
Dosage: 3–5 mg/kg daily IV if no urinary tract involvement[12]
Contraindications
This product is contraindicated in those patients who have shown hypersensitivity to amphotericin B or any other component in the formulation unless, in the opinion of the physician, the condition requiring treatment is life-threatening and amenable only to amphotericin B therapy.
Warnings
WARNING
See full prescribing information for complete Boxed Warning.
This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts.
Amphotericin B for Injection should no be given in doses greater than 1.5 mg/kg.
EXERCISE CAUTION to prevent inadvertent overdosage, which may result in potentially fatal cardiac or cardiopulmonary arrest. Verify the product name and dosage pre-administration, especially if dose exceeds 1.5 mg/kg.
Amphotericin B is frequently the only effective treatment available for potentially life-threatening fungal disease. In each case, its possible life-saving benefit must be balanced against its untoward and dangerous side effects. EXERCISE CAUTION to prevent inadvertent Amphotericin B overdose, which may result in potentially fatal cardiac or cardiopulmonary arrest. Verify the product name and dosage especially if dose exceeds 1.5 mg/kg.
Adverse Reactions
Clinical Trials Experience
Although some patients may tolerate full intravenous doses of amphotericin B without difficulty, most will exhibit some intolerance, often at less than the full therapeutic dose. Tolerance may be improved by treatment with aspirin, antipyretics (e.g., acetaminophen), antihistamines, or antiemetics. Meperidine (25 to 50 mg IV) has been shown in some patients to decrease the duration of shaking chills and fever that may accompany the infusion of amphotericin B. Administration of amphotericin B on alternate days may decrease anorexia and phlebitis.
Intravenous administration of small doses of adrenal corticosteroids just prior to or during the Amphotericin B infusion may help decrease febrile reactions. Dosage and duration of such corticosteroid therapy should be kept to a minimum.
Addition of heparin (1000 units per infusion), and the use of a pediatric scalp-vein needle may lessen the incidence of thrombophlebitis. Extravasation may cause chemical irritation.
The adverse reactions most commonly observed are:
Body as a Whole
Fever (sometimes accompanied by shaking chills usually occurring within 15 to 20 minutes after initiation of treatment)
Nephrocalcinosis. These usually improve with interruption of therapy. However, some permanent impairment often occurs, especially in those patients receiving large amounts (over 5 g) of amphotericin B or receiving other nephrotoxic agents.
In some patients hydration and sodium repletion prior to amphotericin B administration may reduce the risk of developing nephrotoxicity. Supplemental alkali medication may decrease renal tubular acidosis.
The following adverse reactions have also been reported:
↑ [Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America] Check |url= value (help). Missing or empty |title= (help)
↑ [Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America] Check |url= value (help). Missing or empty |title= (help)